MCW Cancer Center leads change in Medicare policy for older patients with MDS in need of alloHCT

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Centers for Medicare & Medicaid Services recently issued a decision to expand Medicare coverage for allogeneic hematopoietic stem cell transplants for eligible Medicare patients with myelodysplastic syndromes, based on decades-long research led by investigators at the Medical College of Wisconsin Cancer Center, in collaboration with investigators in the Blood and Marrow Transplant Clinical Trials Network and advocacy experts at the American Society of Hematology, American Society for Transplantation and Cellular Therapy, and the National Marrow Donor Program.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login